Interleukin-1α induces immunosuppression by mesenchymal stem cells promoting             the growth of prostate cancer cells.
Mesenchymal stem cells (MSCs) are generally used in tissue engineering,             regenerative medicine and therapy for immune disorder disease. MSCs are also employed             as drug carriers for tumor therapy due to their ability to migrate to tumor tissue.             However, due to the immunosuppressive function of MSCs, the application of MSCs             in prostate cancer therapy remains limited. In this study, we investigated the             underlying mechanism by which MSCs enable prostate cancer cells to escape from             immune surveillance in the inflammatory microenvironment. Firstly, we demonstrated             that compared with the control groups, MSCs pretreated with IL-1α effectively             promoted the growth of the mouse prostate cancer cell line RM-1 in vivo. Furthermore,             when RM-1 prostate cancer cells were co-injected with MSCs pretreated with IL-1α,             tumor incidence significantly increased in allogeneic recipients. In addition,             we investigated the mechanism through which MSCs promote the ability of RM-1 cells             to escape from immune injury. The results revealed that IL-1α led to the upregulation             of TGF-β in MSCs. The inflammatory cytokine-induced promotive effect of MSCs on             RM-1 cells in vivo was inhibited by TGF-β siRNA. The results of our study suggest             that inflammatory cytokines induce the immunosuppressive function of MSCs which             enables prostate cancer cells to escape from immune injury.
Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, PR China.
Jiwen
J
Cheng
Ling
L
Li
Yan
Y
Liu
Zhirou
Z
Wang
Xiaodong
X
Zhu
Xianzhong
X
Bai
D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D007165:Immunosuppression Therapy; D053582:Interleukin-1alpha / Q000494:pharmacology*; D008297:Male; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D014184:Transplantation, Homologous; D015854:Up-Regulation
D053582:Interleukin-1alpha; D034741:RNA, Small Interfering; D016212:Transforming Growth Factor beta